Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Ovarian Neoplasms

  Free Subscription


05.02.2024

1 Ann Oncol
2 Cancer
2 Curr Treat Options Oncol
1 Discov Oncol
4 Gynecol Oncol
1 Int J Gynaecol Obstet
1 Int J Oncol
1 J Clin Oncol
1 Oncogene
1 Oncol Rep
1 Oncology (Williston Park)
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Oncol

  1. LEDERMANN JA, Matias-Guiu X, Amant F, Concin N, et al
    ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
    Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7. doi: 10.1016/j.annonc.2023.
    PubMed         Abstract available


    Cancer

  2. MUTCH D, Voulgari A, Chen XM, Bradley WH, et al
    Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
    Cancer. 2024 Jan 30. doi: 10.1002/cncr.35222.
    PubMed         Abstract available

  3. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    PubMed         Abstract available


    Curr Treat Options Oncol

  4. RATNAPARKHI R, Javellana M, Jewell A, Spoozak L, et al
    Evaluation of Homologous Recombination Deficiency in Ovarian Cancer.
    Curr Treat Options Oncol. 2024 Feb 1. doi: 10.1007/s11864-024-01176.
    PubMed         Abstract available

  5. ANASTASIO MK, Shuey S, Davidson BA
    Antibody-Drug Conjugates in Gynecologic Cancers.
    Curr Treat Options Oncol. 2024;25:1-19.
    PubMed         Abstract available


    Discov Oncol

  6. CAO M, Xiao L, Chen S, Huang J, et al
    Characterization of hypoxia-responsive states in ovarian cancer to identify hot tumors and aid adjuvant therapy.
    Discov Oncol. 2024;15:23.
    PubMed         Abstract available


    Gynecol Oncol

  7. TUBRIDY EA, Eiva MA, Liu F, Omran DK, et al
    CD137+ tumor infiltrating lymphocytes predicts ovarian cancer survival.
    Gynecol Oncol. 2024;184:74-82.
    PubMed         Abstract available

  8. WEHN AK, Qiu P, Lunceford J, Yarunin A, et al
    Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer.
    Gynecol Oncol. 2024;184:67-73.
    PubMed         Abstract available

  9. MOFFAT GT, Kong W, MacKay HJ, McGee J, et al
    Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
    Gynecol Oncol. 2024;184:51-56.
    PubMed         Abstract available

  10. MUSACCHIO L, Palluzzi E, Di Napoli M, Lauria R, et al
    Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
    Gynecol Oncol. 2024;184:24-30.
    PubMed         Abstract available


    Int J Gynaecol Obstet

  11. BRENT SE, McGee J, Vicus D, Kim R, et al
    Rates of genetic consultation in high-grade serous ovarian cancer patients in the era of PARP inhibitor therapy: A population-based study.
    Int J Gynaecol Obstet. 2024 Jan 29. doi: 10.1002/ijgo.15391.
    PubMed         Abstract available


    Int J Oncol

  12. GENG D, Zhou Y, Wang M
    Advances in the role of GPX3 in ovarian cancer (Review).
    Int J Oncol. 2024;64:31.
    PubMed         Abstract available


    J Clin Oncol

  13. PAVLIK EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR, et al
    Compelling Story of Ovarian Cancer Screening.
    J Clin Oncol. 2024 Feb 2:JCO2302424. doi: 10.1200/JCO.23.02424.
    PubMed        


    Oncogene

  14. WU J, Wu Y, Chen S, Guo Q, et al
    PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/beta-catenin signalling pathway.
    Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02943.
    PubMed         Abstract available


    Oncol Rep

  15. HOU Y, Zhao X, Nie X
    Enhancing the therapeutic efficacy of NK cells in the treatment of ovarian cancer (Review).
    Oncol Rep. 2024;51:50.
    PubMed         Abstract available


    Oncology (Williston Park)

  16. LA SPINA S, Scollo P, Pecorino B, Lombardo V, et al
    Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy.
    Oncology (Williston Park). 2024;38:15-19.
    PubMed         Abstract available


    PLoS One


  17. Expression of Concern: Minocycline Suppresses Interleukine-6, Its Receptor System and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of Ovarian Cancer Cells: In Vitro and In Vivo Studies.
    PLoS One. 2024;19:e0298444.
    PubMed        

  18. YONG CM, Yehgambaram PAP, Lee SWH
    Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
    PLoS One. 2024;19:e0298130.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.